# Appendix H. Applicability of Individual Studies

Table 47. Evaluation of applicability for individual randomized controlled trials

| Author,Year | Effectiveness Study Designation and Composite Score | Effectiveness Study Criteria Met | Applicability Limitation Category | Specific Factors Limiting Applicability |
| --- | --- | --- | --- | --- |
| CT5, 2012 | Study Designation:Efficacy studyComposite Score: 4of 7 | 1. Assessed final health outcomes
2. Adequate study duration with clinically relevant treatments
3. Assessed adverse outcomes
4. Used intention-to-treat analysis
 | Population, Outcomes, Setting | * + High male to female ratio (M: 79.5% F: 20.5%)
	+ More stringent eligibility criteria
	+ Duration of followup for final health outcomes (Psychological outcomes – 24 weeks)
	+ Duration of followup for adverse health outcomes (AST, ALT, HTN, Injection site reaction, Infections – NR)
	+ Conducted in Korea
 |
| Barker, 2011 | Study Designation:Effectiveness studyComposite Score: 6 of 7 | 1. Enrolled primary care population
2. Assessed final health outcomes
3. Adequate study duration with clinically relevant treatments
4. Assessed adverse outcomes
5. Adequate sample size
6. Used intention-to-treat analysis
 | Population, Outcomes, Setting | * + More stringent eligibility criteria
	+ Duration of followup for final health outcomes (MACE, diabetes – 26 weeks)
	+ Duration of followup for adverse outcomes (malignancy, infections – 26 weeks)
	+ Conducted in Europe
 |
| Caproni, 2009 | Study Designation:Efficacy studyComposite Score: 3 of 7 | 1. Enrolled primary care population
2. Assessed adverse outcomes
3. Used intention-to-treat analysis
 | Population, Outcomes, Setting | * + More stringent eligibility criteria
	+ Did not assess final health outcomes
	+ Duration of followup for intermediate health outcomes (PASI – 12 weeks)
	+ Inadequate sample size
	+ Conducted in Italy
 |
| Gisondi, 2008a | Study Designation:Efficacy studyComposite Score: 4 of 7 | 1. Enrolled primary care population
2. Adequate study duration with clinically relevant treatments
3. Assessed adverse outcomes
4. Used intention-to-treat analysis
 | Population, Outcomes, Setting | * + More stringent eligibility criteria
	+ Did not assess final health outcomes
	+ Inadequate sample size
	+ Conducted in Italy
 |
| Saurat, 2008 | Study Designation:Effectiveness studyComposite Score: 6 of 7 | 1. Enrolled primary care population
2. Assessed final health outcomes
3. Adequate study duration with clinically relevant treatments
4. Assessed adverse outcomes
5. Adequate sample size
6. Used intention-to-treat analysis
 | Population, Outcomes, Setting | * + More stringent eligibility criteria
	+ Duration of followup for final health outcomes (mortality – 70 days after last treatments)
	+ Duration of followup for adverse events (infections – 70 days after last followup)
	+ Conducted in Europe and Canada
 |